Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 6HR+/HER2- Advanced Breast Cancer 2Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1HER2-positive Breast Cancer 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

toripalimab 1palbociclib 1dalpiciclib 1Sirolimus 1Paclitaxel 1Injections 1Fulvestrant 1Docetaxel 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Breast Cancer × dalpiciclib × Clear all
NCT05431504 2022-06-24

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
53 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡